Aug. 17, 2009 ImmunoFrontier filed an Application of CHP-NY-ESO-1 for Phase I Study with PMDA to develop for esophageal cancer. Mar.10, 2009 CHP-NY-ESO-1 project was chosen for NIBIO's "Practical Application Research Supporting Program for Medicine and Medical Device". Mar.9, 2009 ImmunoFrontier was reported in International Pharmaceutical Intelligence as challenging company titled "Developing vaccines and immunotherapeutic drugs based on CHP". Mar.2, 2009 Article about ImmunoFrontier was published in Nikkei Biotechnology & Business Online. Apr.20, 2009 Japanese web-site was renewed. Apr.20, 2009 Our Head Office relocated to new address.